CellWell record HH-485826
Targeting Bruton's Tyrosine Kinase (BTK) in Autoimmunity: Achievements, Opportunities and Challenges
Sebastian Torke; Sarah Dybowski; Martin S Weber
2026
In plain language
This review found BTK inhibitors showed promising effects on inflammatory activity in multiple sclerosis, but several failed primary endpoints in rheumatoid arthritis and lupus, with liver-toxicity signals in late-stage trials.
- Evidence
- Emerging
- Design
- Expert review
Cite this record: https://thecellwell.org/studies/HH-485826
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.